Specialty Finance / Distressed Real Estate
High Interest Rate
Mortgages
Mortgage Loan Investing
- Opportunity to invest in or acquire high interest rate mortgages with ~12% yield (8% to investor)
- LTVs below 80%; initial package of $23M; consistent flow of $5M per month growing to $8M by July/August, average balance $200K
- Loan types are a) single family; b) investor (fix and flip or rentals); c) Foreign National. Geographies include FL; GA; CO and soon MA – Originator will replace any 90+ day past due loans
White Label Hotel
Manager
Distressed Hotel Acquisitions & Leasing – Germany
- Opportunity to co-invest in hospitality property leasing company run by a highly successful and experienced team with over 20 years of history
- The operator needs a capital partner to support leases (~$30MM term loan)
- EBITDA of firm is ~10MM and growing rapidly
- This would also provide capital partner with the ability to acquire off-market turnaround hotels around Europe
Pipeline of Hospitality
Assets in Europe
Hospitality Assets – Europe
- Opportunity to acquire pipeline of 43 hotels in Spain, UK, Italy, France, Denmark and Turkey for ~$2.5BN
- Most opportunities are discrete and independent of each other. Most have the option of long term leases or management agreements
- Four of the properties are in different stages of development. The other properties are established and functioning 4 and 5 star hotels
Short Term Commercial
RE Loans
Asset Investment
- Opportunity to invest with a leading originator and investment manager in the sector
- Can be managed accounts. Loans 1-3yrs. Net levered yields 12-13%
- Note: investors need to be willing to give up a lot of discretion. Unlikely PE/HF a fit if already in RE
- Can be LP capital
CHP / COGEN Financing
Projects requiring ~$30MM
- Opportunity to finance 5 CHP / Cogeneration and green energy projects that are approved by NYSERDA and utility refunds
- Engineering firm has a track record of over 100 projects in the NY area
- Projects will be repaid through shared savings agreements with credit worthy counterparties
- Mid-to-long term interest in partnering to create a leasing company for their projects and proven shared savings technologies
Real Estate backed
portfolio loans in Italy
Loan Acquisition ($40 to $200M+ investments
- Opportunity to invest in Real Estate back portfolio loans
- Experienced team with personnel in UK and Italy. 5+ years of advising larges fund investors in Europe
- Looking for actively managed funds to provide capital on specific deal opportunities and pay fee/promote
Healthcare / Med-Tech
OTC Pharmaceutical Company
- Opportunity to invest in a management buyout of a growth company that sells private label OTC, prescription drugs, health & beauty products.
| 2018 Budget | 2019 Projection |
Net Sales | $40,130,000 | $42,515,440 |
EBITDA | $2,700,000/Adj $3,469,000 | $3,928,902 |
Specialty
Pharmaceutical/Pain
- Company is raising $6-$10M in Series B preferred, to launch “better than generic” with Catalent quick dissolve technology
- Capital will be used to move a combination drug candidate for the chronic pain market called Bucam and a version of Suboxone called Bunal
- Comparable product is selling ~£750M through Indivior (London INDV.L) for the opiod addiction market
Antimicrobial product
Private Company
- Potential to capture a significant share of the global antibiotic/antimicrobial market, now $42 billion.
- The Company has recently completed a Phase 1/2a clinical trial using Nu-3 to treat infected diabetic foot ulcers with promising results.
- Company is looking to raise $20-$30M in equity/convertible preferred.
Clinical stage Cancer
drug company
$10-$30M of Common or Preferred
- Clinical stage cancer drug company with a strong pipeline composed of newly patented Immuno-Oncology (IO) and a world class IO drug discovery platform.
- OBT has generated $60M in milestone and licensing revenue from Big Pharma (Sanofi and Menarini) with another $12M from Boehringer Ingelheim (BI) coming in 2019 and OBT has collaborated with Amgen, Immunogen, BMS
- 2 drug candidates are in clinical trials and 3 IO candidate drugs are close
Growing Sales Laprascopic
device company
$10-$20M series B
- Abdominal keyhole surgery through the abdomen (20m procedures p.a).
- The single use OpClear is the only device that keeps the scope lens clear of during a procedure.
- 5,000,000 procedures p.a., FDA 510k: 3/15/18, Distribution under negotiation
- Lead hospitals Texas & NY, Robotics development partnership
- Current sales approx £ 1M
Growth Equity / Fintech
Structured Consumer
Deposit Fintech Firm
Sale of Company or Strategic Partnership
- Opportunity to invest in or acquire the only front-office & back-office Fintech firm that produces structured CDs for U.S. Banks and Credit Unions
- Their solution has been successfully implemented by a major Bank that issued over $1BN of the paper within months. This allowed the client bank to lower its cost of deposits while increasing its Core Deposits
- Looking for a M&A partner or strategic investor that can provide distribution capabilities for their product
Mortgage Equity Investment
A Round ($20MM)
Mortgage Equity Investment
- Mortgage Equity Investment firm raising A round capital ($20MM)
- Also interested in funding of equity extraction financing for existing over-equitized home owners or equity for first time home buyers
Human Resources SaaS
Sale of Company
- HR Saas with separate modules that can be integrated to other systems like Worday, SAP, Oracle
- Out of the box configurable solution for A-list clients : Dropbox, NYSE, LinkedIN, Universal, UBER, Two Sigma, …
- $2M revenues in 2017, expected to hit $4/$5M revenues in 2018 with 60% EBITDA margin
Consumer Business & Services
Solar (EPC): Engineering
Procurement and Construction
Public Company: Convertible Preferred Stock
- Completed over 25 MW of commercial scale solar projects in NY
- Large corporate and REIT customers (owners of RE > 250,000 sf)
- Seeking $5-10M in Debt, Convertible Pfd Stock or equity
- 2018 Revenue: apprx $10M, EBITDA: apprx $3.5M
- M&A offers apprx $17M
Shipping / Tanker Sector
Sale and Leaseback of
8 Offshore Vessels
Junior / Senior / Unitranche
- Raising $56M capital (junior/ senior or unitranche) to finance the purchase of 8 offshore utility vessels as part of a 5 year sale and lease back transaction
- The 8 vessels are on long term charter to Aramco
- Seller / lessee is publicly quoted shipping company
- Aramco cash flows sufficient to fully amortize junior financing reducing residual value risk